This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum


  • 00
  • 00
  • 00
  • 00
7-9 March 2023
Westin Miyako KyotoKyoto, Japan

Chandra Vargeese, PhD
Chief Technology Officer at WAVE Life Sciences


Dr. Vargeese is one of the industry’s leading oligonucleotide chemists with approximately 30 years of oligonucleotide research experience, authoring numerous scientific publications and patents in the field. Dr. Vargeese joined Wave Life Sciences in 2014 and was named Chief Technology Officer in 2020. She is responsible for the advancement of Wave’s PRISM platform, which is foundational to all of Wave’s drug discovery and development efforts. Before joining Wave, Dr. Vargeese served as Executive Director of Chemistry and Delivery, RNA Therapeutics Division at Novartis. She led siRNA delivery as Senior Director in the RNA Therapeutics division at Merck. She joined Merck through its $1.1 billion acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen® (pegaptanib), an approved therapy for wet AMD. She earned a PhD in organic chemistry at the Indian Institute of Science, Bangalore, India, and completed post-doctoral work at University of Rhode Island.

Agenda Sessions

  • Impact of Guanidine-containing Backbone Linkages on Oligonucleotide Silencing, Splicing and RNA Base Editing Modalities